INVESTIGATION OF IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Г. М. Тарасова(Association of Rheumatologists of Russia), Т. В. Попкова, Е. А. Асеева(Association of Rheumatologists of Russia), M. Cherkasova(Association of Rheumatologists of Russia), Д. В. Буханова(Association of Rheumatologists of Russia), Т. М. Reshetnyak(Association of Rheumatologists of Russia), S. K. Solovyev, Б. С. Белов(Association of Rheumatologists of Russia)
Cited by 7
Related Papers
RATIONAL USE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS. CLINICAL GUIDELINES
|Rheumatology Science and Practice|2018|151
Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia
|Rheumatology Science and Practice|2021|54
COVID-19: the new challenge for rheumatologists
|Modern Rheumatology Journal|2020|30
Comorbid infections in rheumatic diseases (according to FSBI RIR named after V.A. Nasonova)
|Meditsinskiy sovet = Medical Council|2019|14
Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review
|Rheumatology Science and Practice|2021|14